Nuvectis Pharma recaps poster presentation highlights on NXP800

Nuvectis Pharma provided highlights from the poster presentation of NXP800 that took place yesterday at the American Association for Cancer Research Annual Meeting 2023 in Orlando, FL. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "Cancer of the bile duct, or cholangiocarcinoma, is a serious unmet medical need for which new treatment options are greatly needed. With approximately 10,000 new cases per year in the United States, the clinical management of CCA is complex, with only about 30% of patients eligible for surgical resection and the rest with unresectable disease, which carries a dismal prognosis with a median survival of less than 1 year. Unfortunately, approximately 60% of the patients that do undergo surgical resection experience disease recurrence and face similar outcomes." Mr. Bentsur concluded, "We are excited about the data generated as we continue to evaluate clinical development opportunities for NXP800."